{"Clinical Trial ID": "NCT00005908", "Intervention": ["INTERVENTION 1:", "Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine", "Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 oral twice daily 2-15 for 4 cycles Once the dose was considered too toxic, the following patients were included at dose B.", "INTERVENTION 2:", "Dose B-Cohort 2-Arm 2 Reduced dose-Docetaxel and capecitabine", "Docetaxel 60 mg/m^2 intravenous day 1 capecitabine 937.5 mg/m^2 oral twice daily 2-15"], "Eligibility": ["CRITERIA FOR INCLUSION:", "Patients with prior biopsy are eligible provided the tumour tissue remains adequate for biopsy in this study.", "At least 18 years of age.", "An adequate hematopoietic function as defined by the absolute number of neutrophils greater than 1200/mm^3 and the number of platelets greater than 100,000/mm^3.", "adequate renal function as defined by creatinine below 1.6 mg/dL.", "- Adequate hepatic function as defined by total bilirubin (T.) less than 1.4 mg/dL and serum oxaloacetic glutamic transaminase (SGOT)/serum pyruvic transaminase (SGPT) less than 1.5 times the upper limit of normal and alkaline phosphatase less than 2.5 times the upper limit of normal", "Zubrod Performance status 0-2.", "EXCLUSION CRITERIA:", "A medical or psychiatric condition which, in the opinion of the Principal Investigator, would prevent the administration of chemotherapy may be evaluated by psychiatry or by medical subspecialties, as appropriate.", "Pregnant or lactating women", "Known haemorrhagic disorders", "Hypersensitivity to Tween 80 (Polysorbate)", "A fraction of cardiac ejection below normal limits, myocardial infarction in the last 12 months, or symptomatic arrhythmia requiring medical intervention.", "\u00b7 Prior chemotherapy or hormonal treatment for breast cancer. Patients treated with hormonal chemoprevention (tamoxifene or raloxifene) will be eligible.", "In the last 5 years, active malignancy has been diagnosed (non-melanomatous skin cancer or non-melanomatous skin cancer that has been treated with curative intent will be eligible)."], "Results": ["Performance measures:", "Number of participants with adverse events", "For a detailed list of adverse events, see the Adverse Events module.", "Time limit: 6 years", "Results 1:", "Title of arm/group: Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine", "Description arm/group: Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 oral twice daily 2-15 for 4 cycles Once the dose was considered too toxic, the following patients were included at dose B.", "Total number of participants analysed: 9", "Type of measurement: Number", "Unit of measure: Participants 9", "Results 2:", "Title of the arm/group: Dose B-Cohort 2-Arm 2 Dose reduced-Docetaxel & Capecitabine", "Docetaxel 60 mg/m^2 day intravenously 1 capecitabine 937.5 mg/m^2 orally twice daily 2-15", "Total number of participants analysed: 20", "Type of measurement: Number", "Unit of measure: Participants 20"], "Adverse Events": ["Undesirable Events 1:", "Total: 29/30 (96.67 per cent)", "Febrile neutropenia [1]3/30 (10.00 %)", "- Lymphatic 1/30 (3.33%)", "Diarrhoea (without colostomy) 5/30 (16.67%)", "Abdominal pain or cramps 2/30 (6.67%)", "Colite 1/30 (3.33%)", "Dehydration 1/30 (3.33%)", "Nausea 1/30 (3.33%)", "- Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%)", "- Vomiting 1/30 (3.33%)", "Adverse Events 2:", "- Yeah, that's right."]}